The biphasic release of Xenidate XL matches that of Concerta XL, giving patients the same pattern of efficacy throughout their day and night.1
A single-dose, randomised, open-label, two treatment, five-period, six-sequence crossover study comparing Xenidate XL 54 mg tablets to Concerta XL® 54 mg, which shows the mean plasma concentration of methylphenidate against time curves after administration of the test product and the reference product in 52 healthy subjects under fasting conditions and under fed conditions (test n=54, reference n=108).
Xenidate XL is a proven, high quality, interchangeable generic of its reference product, Concerta XL. All safety data published for Concerta XL can therefore be extrapolated for the use of Xenidate XL.1 Very common (≥1/10) adverse effects include insomnia, nervousness and headache.2 For the full list of adverse events please consult the Xenidate XL Summary of Product Characteristics for each available dose.
See how much you could save switching your Concerta XL patients to Xenidate XL
|Concerta XL||Xenidate XL||Your saving
with Xenidate XL
|% cost decrease|
|NHS indicative||NHS indicative|
Prices correct as of 27.09.18.
Each tablet for the four available Xenidate XL doses (18 mg, 27 mg, 36 mg, 54 mg) is a similar size to its equivalent Concerta XL tablet.4